Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease | 2021-05-23 | Press Releases | Stockhouse

Late-breaker est l’un des 20 résumés de Janssen, dont 16 montrent le profil d’innocuité et l’efficacité de STELARA dans le traitement de la maladie de Crohn et de la colite ulcéreuse à la Digestive Disease Week (DDW) Virtual 2021

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn's Disease
© www.stockhouse.com

💬 Laisser un commentaire